ABL Bio Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Sang Hoon Lee
Chief executive officer
₩889.0m
Total compensation
| CEO salary percentage | 60.63% |
| CEO tenure | 10.3yrs |
| CEO ownership | 23.2% |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -₩24b |
| Dec 31 2025 | n/a | n/a | -₩38b |
| Sep 30 2025 | n/a | n/a | -₩29b |
| Jun 30 2025 | n/a | n/a | -₩21b |
| Mar 31 2025 | n/a | n/a | -₩72b |
| Dec 31 2024 | ₩889m | ₩539m | -₩56b |
Compensation vs Market: Sang Hoon's total compensation ($USD585.85K) is below average for companies of similar size in the KR market ($USD1.01M).
Compensation vs Earnings: Insufficient data to compare Sang Hoon's compensation with company performance.
CEO
Sang Hoon Lee
Dr. Sang Hoon Lee, PH D co-founded PharmAbcine, Inc. in 2008 and serves as its Executive Vice President. Dr. Lee founded ABL Bio Inc. in February 2016 and serves as its President and Chief Executive Office...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/22 13:12 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ABL Bio Inc. is covered by 4 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jisoo Lee | DAOL Investment & Securities Co., Ltd. |
| Haesoon Kwon | Eugene Investment & Securities Co Ltd. |
| Hee Ryeong Jung | Kyobo Securities Co., Ltd |